545 related articles for article (PubMed ID: 37441462)
1. Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies.
Ji Z; Shen J; Lan Y; Yi Q; Liu H
MedComm (2020); 2023 Aug; 4(4):e308. PubMed ID: 37441462
[TBL] [Abstract][Full Text] [Related]
2. Effect of traditional Chinese medicine in osteosarcoma: Cross-interference of signaling pathways and potential therapeutic targets.
Liu Y; Jiang B; Li Y; Zhang X; Wang L; Yao Y; Zhu B; Shi H; Chai X; Hu X; Zhang B; Li H
Medicine (Baltimore); 2024 Jan; 103(3):e36467. PubMed ID: 38241548
[TBL] [Abstract][Full Text] [Related]
3. Andrographolide inhibits the growth of human osteosarcoma cells by suppressing Wnt/β-catenin, PI3K/AKT and NF-κB signaling pathways.
Huang H; Lu Q; Yuan X; Zhang P; Ye C; Wei M; Yang C; Zhang L; Huang Y; Luo X; Luo J
Chem Biol Interact; 2022 Sep; 365():110068. PubMed ID: 35917943
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles of long non-coding RNAs in osteosarcoma.
Liao X; Wei R; Zhou J; Wu K; Li J
Front Mol Biosci; 2024; 11():1327459. PubMed ID: 38516191
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK; Yamamichi T; Yustein JT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511127
[TBL] [Abstract][Full Text] [Related]
6. Nitazoxanide inhibits osteosarcoma cells growth and metastasis by suppressing AKT/mTOR and Wnt/β-catenin signaling pathways.
Ye C; Wei M; Huang H; Wang Y; Zhang L; Yang C; Huang Y; Luo J
Biol Chem; 2022 Sep; 403(10):929-943. PubMed ID: 35946850
[TBL] [Abstract][Full Text] [Related]
7. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy.
Ma Y; Ren Y; Han EQ; Li H; Chen D; Jacobs JJ; Gitelis S; O'Keefe RJ; Konttinen YT; Yin G; Li TF
Biochem Biophys Res Commun; 2013 Feb; 431(2):274-9. PubMed ID: 23291185
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
10. microRNA-377-3p inhibits osteosarcoma progression by targeting CUL1 and regulating Wnt/β-catenin signaling pathway.
Liang K; Liao L; Liu Q; Ouyang Q; Jia L; Wu G
Clin Transl Oncol; 2021 Nov; 23(11):2350-2357. PubMed ID: 34133001
[TBL] [Abstract][Full Text] [Related]
11. Schisandrin B suppresses osteosarcoma lung metastasis
Wang Y; Chen J; Huang Y; Yang S; Tan T; Wang N; Zhang J; Ye C; Wei M; Luo J; Luo X
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029287
[TBL] [Abstract][Full Text] [Related]
12. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
13. MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
Lopes LJS; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia-Filho RJ; Toledo SRC
Mol Carcinog; 2017 Jun; 56(6):1630-1641. PubMed ID: 28112450
[TBL] [Abstract][Full Text] [Related]
14. ALOX5AP suppresses osteosarcoma progression via Wnt/β-catenin/EMT pathway and associates with clinical prognosis and immune infiltration.
Han GD; Dai J; Hui HX; Zhu J
J Orthop Surg Res; 2023 Jun; 18(1):446. PubMed ID: 37344882
[TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt signaling in osteosarcoma.
Zhang J; Yu XH; Yan YG; Wang C; Wang WJ
Clin Chim Acta; 2015 Apr; 444():182-92. PubMed ID: 25704303
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times.
Selvarajah GT; Kirpensteijn J; van Wolferen ME; Rao NA; Fieten H; Mol JA
Mol Cancer; 2009 Sep; 8():72. PubMed ID: 19735553
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
19. Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma.
Dana PM; Sadoughi F; Asemi Z; Yousefi B
Curr Med Chem; 2022; 29(25):4436-4444. PubMed ID: 35139778
[TBL] [Abstract][Full Text] [Related]
20. Targeting Signaling Pathway by Curcumin in Osteosarcoma.
Farnood PR; Pazhooh RD; Asemi Z; Yousefi B
Curr Mol Pharmacol; 2023; 16(1):71-82. PubMed ID: 35400349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
